PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition